北京市結(jié)核病胸部腫瘤研究所內(nèi)科學(xué)2022年碩士研究生導(dǎo)師介紹：王敬慧

• 2025考研復(fù)試標(biāo)準(zhǔn)班
• 26考研全科上岸規(guī)劃營「擇校▪規(guī)劃▪備考」
• 北京市結(jié)核病胸部腫瘤研究所2026考研專業(yè)課復(fù)習(xí)資料「真題▪筆記▪講義▪題庫」

內(nèi)科學(xué)

王敬慧，女，北京胸科醫(yī)院腫瘤二科主任醫(yī)師，醫(yī)學(xué)博士，副教授，碩士研究

生導(dǎo)師，腫瘤研究中心副主任。

長期從事肺癌等胸部腫瘤的臨床、科研和教學(xué)工作，對胸部腫瘤的診治具有豐富的臨床經(jīng)驗(yàn)。主要研究方向?yàn)榉伟┟庖呒胺伟﹤�(gè)體化治療。共計(jì)發(fā)表論文80余篇，以第一或通訊作者在NatCommu、LungCancer等中外雜志上發(fā)表論文30余篇，并在ASCO、WCLC等會(huì)議上做壁報(bào)交流及口頭發(fā)言。曾獲北京市衛(wèi)生局十百千“百”層次人才資助。獲批第三屆通州兩高人才。指導(dǎo)或協(xié)助培養(yǎng)碩士及博士研究生10余名。

代表作：

1.Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun. 2018 Aug 6;9(1):3114. doi: 10.1038/s41467-018-05327-w. Erratum in: Nat Commun. 2019 Jan 29;10(1):552. PMID: 30082701; PMCID: PMC6079068.

2.Ma L, Li H, Wang D, Hu Y, Yu M, Zhang Q, Qin N, Zhang X, Li X, Zhang H, Wu Y, Lv J, Yang X, Yu R, Zhang S, Wang J. Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs. Front Oncol. 2021 Mar 25;11:643199. doi: 10.3389/fonc.2021.643199. PMID: 33842353; PMCID: PMC8030263.

3.Song H, Liu B, Dong B, Xu J, Zhou H, Na S, Liu Y, Pan Y, Chen F, Li L, Wang J. Exosome-Based Delivery of Natural Products in Cancer Therapy. Front Cell Dev Biol. 2021 Mar 2;9:650426. doi: 10.3389/fcell.2021.650426. PMID: 33738290; PMCID: PMC7960777.

4.Liu B, Wang Z, Gu M, Zhao C, Ma T, Wang J. GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy. Front Oncol. 2021 Apr 20;11:629333. doi: 10.3389/fonc.2021.629333. PMID: 33959497; PMCID: PMC8095246.

5.Zhang X, Lv J, Wu Y, Qin N, Ma L, Li X, Nong J, Zhang H, Zhang Q, Yang X, Shi H, Wang J, Zhang S. HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib. Front Oncol. 2020 Jul 31;10:1162. doi: 10.3389/fonc.2020.01162. PMID: 32850330; PMCID: PMC7411254.